Showing results (151-160 of 240) with videos related to
Sort By:
Pageof 24
Pulmonary Circulation|February 12, 2024
Using PAH-SYMPACT to assess quality of life in patients with pulmonary hypertension associated with chronic lung diseaseMorgan E Bailey, Louise Durst, Hector R Cajigas, et al.Transplantation|November 27, 2008
Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograftEugenia Raichlin, Krishnaswamy Chandrasekaran, Walter K Kremers, et al.European Journal of Human Genetics : EJHG|February 1, 2007
Recurrent rearrangements in the proximal 15q11-q14 region: a new breakpoint cluster specific to unbalanced translocationsCécile Mignon-Ravix, Danielle Depetris, Judith J Luciani, et al.Journal of the American Heart Association|April 27, 2022
Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association RegistryKevin Y Chang, Sue Duval, David B Badesch, et al.Pulmonary Circulation|November 16, 2022
Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)Vallerie V McLaughlin, Richard Channick, Nick H Kim, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 14, 2012
World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung TransplantationJames C Fang, Teresa DeMarco, Michael M Givertz, et al.American Heart Journal|May 3, 2005
Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failureRobert P Frantz, Lyle J Olson, Diane Grill, et al.Chest|May 26, 2012
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trialVictor F Tapson, Fernando Torres, Fiona Kermeen, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 18, 2003
Clinical predictors of exercise capacity 1 year after cardiac transplantationTat-Chi Leung, Karla V Ballman, Thomas G Allison, et al.Transplantation Proceedings|June 23, 2011
Combined heart and kidney transplantation provides an excellent survival and decreases risk of cardiac cellular rejection and coronary allograft vasculopathyE Raichlin, S S Kushwaha, R C Daly, et al.Pageof 24